Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)
https://www.facingourrisk.org/research-clinical-trials/study/148/olaparib-plus-pembrolizumab-versus-chemotherapy-plus-pembrolizumab-after-first-line-treatment-in-advanced-triple-negative-breast-cancer-keylynk-009
Clinicaltrials.gov identifier:
NCT04191135 (https://clinicaltrials.gov/show/NCT04191135)
Study Contact Information:
For additional information, please contact:
Toll Free Number: 1-888-577-8839 or email: [email protected]
About the Study
This study will look at how people with advanced triple-negative breast cancer (TNBC) respond to different combinations of drugs. The study will look at two different treatment periods:
- Initial period: during this initial study period, participants will receive a combination of chemotherapy and immunotherapy drugs. Participants with stable cancer or an improvement will be able to continue to the next part of the study.
- Followup period: Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead immunotherapy plus a type of targeted therapy known as a PARP inhibitor during the follow-up period.
NOTE: This study is no longer enrolling patients.
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is Not Open To:
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.